RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: : Phase I trial to study the effectiveness of gallium nitrate in young patients who have malignant brain tumors, neuroblastoma, rhabdomyosarcoma, non-Hodgkin's lymphoma, or refractory solid tumor.
OBJECTIVES: I. Determine the safety and side effects of gallium nitrate (GAN) when used as an anticancer agent in pediatric patients with refractory solid tumors, including malignant brain tumors, neuroblastoma, rhabdomyosarcoma, and non-Hodgkin's lymphoma. II. Evaluate these side effects in these patients. OUTLINE: Single-Agent Chemotherapy. Gallium Nitrate, GAN, NSC-15200. PROJECTED ACCRUAL: At least 3 patients will be accrued at each dose studied.
Study Type
INTERVENTIONAL
Purpose
TREATMENT
Enrollment
3
Marlene & Stewart Greenebaum Cancer Center, University of Maryland
Baltimore, Maryland, United States
Boston Floating Hospital Infants and Children
Boston, Massachusetts, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.